^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD7 overexpression

    i
    Other names: CD7, CD7 Molecule , T-Cell Leukemia Antigen, T-Cell Antigen CD7, T-Cell Surface Antigen Leu-9, CD7 Antigen (P41), P41 Protein, GP40, TP41, CD7 Antigen, LEU-9, Tp40
    Entrez ID:
    924
    Related biomarkers:
    Expression
    9ms
    Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia. (PubMed, Am J Clin Pathol)
    Acute myeloid leukemia with altered SRSF2 shows a variable degree of morphologic dysplasia without uniform immunophenotypic aberrancies. SRSF2 mutations appear to be independent poor prognostic factors, but allo-SCT has improved the clinical outcomes in patients with SRSF2-mutant AML.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • STAG2 (Stromal Antigen 2) • NCAM1 (Neural cell adhesion molecule 1) • CD7 (CD7 Molecule)
    |
    NPM1 mutation • ASXL1 mutation • SRSF2 mutation • STAG2 mutation • NCAM1 expression • CD33 expression • CD7 overexpression • NCAM1 overexpression
    over2years
    A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) (ASH 2021)
    All patients will receive a single infusion of WU-CART-007 cells on day 1 following a lymphodepleting conditioning therapy consisting of fludarabine and cyclophosphamide on days -5 to -3. Response will be assessed on Cycle 1 Day 28 (± 1 days), and at Months 3, 6, 12, and 24, by bone marrow aspirate and biopsy and PET/CT if indicated. Response will be defined as per modified NCCN Guidelines Version 2.2020.
    Clinical • P1/2 data • CAR T-Cell Therapy • IO biomarker
    |
    CD7 (CD7 Molecule)
    |
    CD7 overexpression
    |
    cyclophosphamide • fludarabine IV • WU CART 007
    over2years
    A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma (ASH 2021)
    Autologous CD7 CAR-T represents a promising immunotherapy for r/r T-ALL/LBL and exhibited encouraging clinical efficacy and safety in treating r/r T-ALL/LBL and ETP-ALL/LBL.
    Clinical • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 overexpression
    |
    CD7-CAR-T
    almost3years
    [VIRTUAL] A single-arm, open-label, pilot trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-lymphoblastic leukemia/lymphoma (ICML 2021)
    Autologous CD7 CAR-T is a novel immunotherapy for r/r T-ALL/LBL and exhibited encouraging clinical efficacy and safety in treating r/r T-ALL/LBL and ETP-ALL/LBL.
    Clinical • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 overexpression
    |
    CD7-CAR-T
    almost3years
    Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. (PubMed, Int Immunopharmacol)
    Oral administration of itraconazole and sulfamethoxazole was performed from day 0 after CAR-T cell infusion...Although grade 1 cytokine-release syndrome (CRS) was diagnosed, it was successfully treated with ibuprofen...After complete remission, the patient received hematopoietic stem cell transplantation (HSCT) and has recovered well to thisdate. Overall, this report suggested that 4SCAR7 could be a safe and effective strategy for the treatment of pediatric patients with high-risk T-cell malignancies.
    Clinical • Journal • CAR T-Cell Therapy • IO biomarker
    |
    KMT2A (Lysine Methyltransferase 2A) • CD7 (CD7 Molecule) • MLLT1 (MLLT1 Super Elongation Complex Subunit)
    |
    CD7 overexpression • MLL fusion
    |
    itraconazole